-transparent.png){kind=logo}
Sixty-three children with ALL in CCR and treated according to a standard therapy protocol were immunized with the 14-valent pneumococcal vaccine. Forty-six children were vaccinated 1, 3, or 6 months following initial induction remission; 15 were vaccinated 4-6 weeks following successful completion of 30 months of antileukemia therapy; and two were vaccinated at the time of diagnosis. Response to the vaccine was suboptimal and by the 6-month follow-up there were only two serotypes for which more than half the patients tested had greater than or equal to 300 ng antibodies N/ml.
Related Publications
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
June 2018,
Human vaccines & immunotherapeutics,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
June 2021,
Pediatric blood & cancer,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
August 1975,
The Journal of pediatrics,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
August 1972,
Revista paulista de medicina,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
August 1975,
Cancer,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
August 1981,
Southern medical journal,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
April 1978,
Mayo Clinic proceedings,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
January 1988,
American journal of diseases of children (1960),
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
November 1982,
Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
S Feldman, and
W Malone, and
R Wilbur, and
G Schiffman
January 1975,
Medical and pediatric oncology,
